Lv610
2326 积分 2021-07-30 加入
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
1天前
已完结
Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer
6天前
已完结
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
7天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
24天前
已完结
The changing therapeutic landscape of small-cell lung cancer
1个月前
已完结
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
2个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
2个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
2个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial
2个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial
2个月前
已关闭
皖公网安备34019202002308
